12.48

2.83% -0.3981

Urogen Pharma Ltd (URGN)

Overview News Price History Option Chain Financials Discussions Forecast

Urogen Pharma Ltd stock is traded at $12.48, with a volume of 104.91K. It is down -2.83% in the last 24 hours and up +2.58% over the past month. UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Previous Close:

$12.88

Open:

$12.86

24h Volume:

104.91K

Relative Volume:

0.19

Market Cap:

$546.06M

Revenue:

$82.71M

Net Income/Loss:

$-102.24M

P/E Ratio:

-2.6671

EPS:

-4.68

Net Cash Flow:

$-76.57M

1W Performance:

+0.28%

1M Performance:

+2.58%

6M Performance:

-4.68%

1Y Performance:

-3.95%

1-Day Range:

$12.50

$12.91

1-Week Range:

$12.00

$13.13

52-Week Range:

$10.60

$20.70

Urogen Pharma Ltd Stock (URGN) Company Profile

Name

Urogen Pharma Ltd

Sector

Healthcare (1180)

Industry

Biotechnology (683)

Phone

972 9 770 7601

Address

9 HA'TA'ASIYA ST, RA'ANANA

Employee

217

Twitter

@UroGenPharma

Next Earnings Date

2024-11-06

Latest SEC Filings

URGN's Discussions on Twitter

Compare URGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
URGN Urogen Pharma Ltd	12.50	546.06M	82.71M	-102.24M	-76.57M	-3.67
VRTX Vertex Pharmaceuticals Inc	462.17	119.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	754.07	82.77B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	620.93	37.02B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	251.47	32.26B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.73	28.24B	3.30B	-501.07M	1.03B	-2.1146

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-22-24	Initiated	Guggenheim	Buy
Feb-08-23	Downgrade	Jefferies	Buy → Hold
Apr-27-22	Initiated	Berenberg	Buy
Apr-16-20	Reiterated	H.C. Wainwright	Buy
Apr-13-20	Reiterated	H.C. Wainwright	Buy
Jan-09-20	Initiated	National Securities	Neutral
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy
Nov-15-17	Reiterated	Oppenheimer	Outperform
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

View All

Urogen Pharma Ltd Stock (URGN) Latest News

Dec 02, 2024

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs - Yahoo Finance

Dec 02, 2024

Dec 01, 2024

URGN (UroGen Pharma) Shares Outstanding (EOP) : 42.19 Mil (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

UroGen Pharma (FRA:UR8) 3-Year Revenue Growth Rate : 74.30% (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

UroGen Pharma (FRA:UR8) Shares Outstanding (EOP) : 36.13 Mil (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

UroGen Pharma (FRA:UR8) PE Ratio without NRI : At Loss (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024

Nov 29, 2024

Vestal Point Capital LP Makes New Investment in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Nov 29, 2024

Nov 28, 2024

UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment - Clinical Trials Arena

Nov 28, 2024

Financial Review: UroGen Pharma (NASDAQ:URGN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) - Defense World

Nov 28, 2024

Nov 27, 2024

Great Point Partners LLC Has $9.64 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

Nov 27, 2024

Nov 26, 2024

JELMYTO shows long-term efficacy in UTUC study - Investing.com India

Nov 26, 2024

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO - Business Wire

Nov 26, 2024

Nov 25, 2024

RA Capital Management, L.P. Increases Stake in UroGen Pharma Ltd - GuruFocus.com

Nov 15, 2024

Analysis of GREAT POINT PARTNERS LLC's Recent Transaction in Uro - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Analysis of COWEN AND COMPANY, LLC's Strategic Reduction in UroG - GuruFocus.com

Nov 14, 2024

RTW INVESTMENTS, LP Acquires Significant Stake in UroGen Pharma Ltd - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

UroGen Pharma: Choice Based On Near-Term High-Value PDUFA - Seeking Alpha

Nov 13, 2024

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business HighlightsURGN Pharmaceuticals, a leading biotech company focused on urothelial and specialty cancers, disclosed its latest financial outcomes for the third quarter ended Septemb - Defense World

Nov 13, 2024

Nov 11, 2024

UroGen Pharma Reports Q3 Results and Drug Progress - TipRanks

Nov 11, 2024

HC Wainwright Forecasts Stronger Earnings for UroGen Pharma - MarketBeat

Nov 11, 2024

Nov 09, 2024

UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Nov 07, 2024